


JABIL POSSESSES A POWERFUL ADVANTAGE:




JABIL is the **ONLY** solution provider offering end to end development, manufacturing and cloud services, streamlining path to market, and providing a unique device focus.



Our scalable digital health platform allows for infinite & **rapid customization** to **serve a wide range of use cases** providing the centralized data & insights that enable Health Care transformation, & **innovation for our customers.**

Jabil's Technology & Manufacturing capabilities with our Digital Health Platform allows us to implement standardized connection protocols across devices, regardless of type, domain or manufacturer, unlocking access to centralized data uniquely rich with manufacturing & device history.



Jabil implements the right **CONNECTIVITY TYPE** to optimize usability, & **STANDARDIZED PROTOCOLS** for seamless connection.

- Generic BLE device connectivity to a mobile application module.
- WiFi/cellular devices: IOT Hub connected with device digital twin.
- Ability to process unstructured data (images, video)



JDHP is rich with device and manufacturing history - adding unique "Device Health" analytics to data solutions.


DIGITAL HEALTH PLATFORM ELEMENTS

DIGITAL TWIN & ANALYTICS

PERFORMANCE MANAGEMENT



PATIENT
DIGITAL TWIN



DEVICE
DIGITAL TWIN



ALGORITHM
DEVELOPMENT



POST MARKET
SURVEILLANCE



DEVICE
PERFORMANCE



IN-FIELD DEVICE
MANAGEMENT

PLUG-N-PLAY



IOT HUB/EDGE



APP DEVELOPMENT



CYBERSECURITY



IDENTITY
MANAGEMENT



INTEROPERABILITY



DEVICE CONNECTIVITY

DATA MANAGEMENT

DEVICE + PATIENT DIGITAL TWINS INTERSECT TO CREATE POWERFUL SOLUTIONS

DEVICE MONITORING

- Geo-location
- Measure device "health"

STREAMLINE DEVELOPMENT

- Device Optimization modeling
- Lifecycle / Supply chain risk mgmt.
- Connected solutions

EFFICIENT POST-MARKET COMPLIANCE

- Performance monitoring
- Real World Data cuts cost

ACCELERATE INNOVATION & STRATEGY capture user behavior, device & consumable:

- adherence & compliance
- geo & site use
- inform consumable /bundling strategies
- understand forces (implants) for innovation
- dose finding / safety profiles
- develop treatment pre-sets
- establish preferred payor codes

BI-DIRECTIONAL CONTROL

- **manage sampling rates to:**
 - preserve battery life
 - capture critical detail when it matters most
- **adjust dose or treatment for precision**

POWER VALUE BASED CARE


improve outcomes & reduce costs

- Population monitoring
 - decentralize care
 - early intervention
 - preserve clinical resources
 - predictive risk- ID vulnerable patients
 - develop population health protocols

ENABLE PRECISION HEALTH INITIATIVES

WIN-WIN: (What I need When I need it) improves outcomes

- predictive risk- ID vulnerable patients
- establish healing models
- dose finding & adjustments



Historical use, & device data analytics drive and Iterative device innovation & enhancement recommendations

JABIL AUTO INJECTOR



VERSATILITY
Supporting a wide range of dosages

CONNECTED
Seamless and intuitive design
tracks and transmits patient
adherence and compliance

- **Lowest Cost** - 20% lower cost than market leading unconnected disposable autoinjectors
- **Broadest** – solution does not require a smartphone or App
- **Simplest** – integrated electronics within the same form factor, allowing the same user operation steps, delivering seamless real-time event tracking

READY
With installed manufacturing
capacity for clinical trials supply

ROBUST
Design shared with
marketed disposable device

VALUE
Lower cost per injection

SUSTAINABLE
Re-useable drive unit minimises waste
and carbon footprint

\$120M



R&D
PRODUCTIVITY

~ a **1% improvement** in R&D Productivity informed by improved decision making about program progression/ termination would equate to **\$120M savings**.¹

\$85M



ACCELERATED
CLINICAL DEVELOPMENT

For a molecule that had peak sales of \$1B this would equate to an upside of circa **\$85M per month** accelerated or delay mitigated.²

24%




REDUCED
STUDY COSTS

Smaller studies maintained by improvements in patient retention and adherence directly influence patient variable costs, representing **24%** of total trial costs.³

1. Di Mazzi et al., Journal of Health Economics, Volume 47, May 2016, Pages 20-33
2. Thadani et al., JAMIA, Volume 16, Issue 6, November 2009, Pages 869-873
3. Sertkaya et al., Report Department of Health & Human Services, July 2014

QFINITY AND DECENTRALIZED CLINICAL TRIALS

Decentralized Clinical Trial Process



Qfinity™

JABIL | MADE **POSSIBLE.**
MADE **BETTER.**